#Dengue #Vaccine #Immunity #ADE #Virus
#Immunogenicity
Dengue is a major arboviral disease affecting
millions of people each year, particularly in tropical and subtropical regions.
Transmitted by Aedes mosquitoes, it can progress to severe forms,
especially during secondary infections with a different viral serotype. This is
partly due to a mechanism known as Antibody-Dependent Enhancement (ADE),
in which non-neutralizing antibodies facilitate the virus's entry into host
cells, worsening the disease.
Current treatments are purely symptomatic, and
available vaccines (such as Dengvaxia) raise safety concerns, particularly in
individuals who have never been previously exposed to the virus. Vaccine
strategies thus face significant immunological limitations.
The main challenge in dengue management lies in
developing live-attenuated vaccines that can induce long-lasting
protective immunity without triggering ADE. The aim of this study is to
explore vaccine candidates specifically designed to eliminate the risk of ADE
while preserving strong immunogenicity.
Can we vaccinate without worsening the disease?
The study uses a genetic engineering approach
to develop live-attenuated dengue vaccines by combining the serotype 2
backbone with the envelope genes of serotypes 1, 3, and 4. These
chimeric vaccines (D2/1, D2/3, D2/4) were tested in vitro and in animal
models (mice and macaques) to assess their safety, their ability to elicit
a protective immune response, and—crucially—their lack of ADE upon secondary
infection with another serotype.
The results show that the vaccine strains
induced a balanced immune response against all four dengue virus serotypes,
without triggering ADE. Furthermore, animal models exposed to a secondary
infection showed no signs of viral enhancement, while the replication of
the attenuated strains remained controlled and non-pathogenic. The
immune response was characterized by the production of neutralizing
antibodies targeting all four serotypes. Among the tested candidates, D2/3
and D2/4 formulations stood out for their favorable safety profiles and
strong immunogenicity.
Read next: Dengue and the Mind: The Silent Storm
A safe vaccine—finally credible?
Dengue remains a global public health priority,
made even more complex by the paradox that some vaccines can worsen the
disease through ADE. This study offers an innovative approach by developing
live-attenuated vaccine strains capable of eliciting strong
cross-protective immunity without triggering ADE.
While the preclinical results are
promising, translating these findings to humans is a crucial next step. In
addition to clinical validation, other major challenges lie ahead:
ensuring large-scale production, maintaining the stability of
recombinant strains, and conducting long-term immune response
assessments.
Despite the current lack of human data, these
vaccine candidates represent a significant advance toward a new
generation of tetravalent dengue vaccines, combining safety and efficacy to address the challenges posed by the virus’s antigenic diversity.
Read next: Severe dengue: a victim of its own defense?
